Biocon Limited has informed the Exchange about Investor Presentation
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon submitted its investor presentation ahead of analyst meets on Feb 25-26, 2026, outlining its FY26 strategy and Q3 FY26 results. The group reported Q3 FY26 revenue of Rs 4,290 crore, up 11% year-on-year, with core EBITDA rising 21% to Rs 1,221 crore (29% margin). Biocon Biologics led growth with 9% revenue growth and 44% EBITDA jump, driven by strong North America Oncology and Immunology sales. The company highlighted progress on integrating Biocon Biologics (now 98% owned), plans to acquire the remaining 2% via share swap and cash. Debt has been actively reduced — Net Debt/EBITDA improved from 4.3x to 2.8x proforma, aided by a Rs 4,500 crore QIP and refinancing that saves Rs 300 crore annually in interest costs.
The presentation reinforces Biocon's deleveraging story and margin expansion roadmap, which should be positive for shareholders. Strong biosimilar launches lined up for 2026 (Semaglutide, Liraglutide, oncology assets) and the proposed business consolidation could drive re-rating, though CRDMO (Syngene) weakness in Q3 and high R&D spend remain near-term watchpoints.